Product Information

CARBIDOPA-LEVO ER 61.25-245 CP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $3.9235 per EA under NDC 70710214201. Its NADAC has been published 40 times since Feb 18, 2026.

FDA first approved this application on Jan 7, 2015.

The High Outlier badge above means this manufacturer's average price in the Carbidopa and Levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

CARBIDOPA-LEVO ER 61.25-245 CP

Carbidopa and Levodopa
$3.9235per EA
High Outlier

Strength

61.25; 245 mg/1; mg/1

NDC

70710214201

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

CARBIDOPA; LEVODOPA

Approval Type

Authorized Generic (NDA)

FDA Application

NDA203312

FDA Approved

1/7/2015

On Market Since

10/20/2025

Pharmacological Classes

Amino Acids
Aromatic
Aromatic Amino Acid

Price Statistics

The NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has been published 40 times since Feb 18, 2026, and over the history we have for it it has risen 3.9%. The table below summarizes its recorded NADAC range and movement.

Current price$3.9235 per EA
All-time high$3.9497 (Nov 11, 2026)
All-time low$3.7464 (Apr 22, 2026)
52-week high$3.9497
52-week low$3.7464
Median price$3.7776
Average price$3.8226
Largest weekly change+1.6% (Jul 22, 2026)
Weeks tracked40
Tracking sinceFeb 18, 2026

Price History

1W

-0.7%

1M

-0.1%

3M

+1.2%

6M

+4.7%

1Y

N/A

3Y

N/A

5Y

N/A

All

+3.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 11%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CARBIDOPA-LEVO ER 61.25-245 CP?

The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 61.25-245 CP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $3.9235 per EA (NDC 70710214201), effective Nov 18, 2026.

How has the price of CARBIDOPA-LEVO ER 61.25-245 CP changed over time?

Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has risen 3.9%. It has been tracked across 40 weekly CMS publications since Feb 18, 2026.

What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 61.25-245 CP?

Since Feb 18, 2026, the NADAC for CARBIDOPA-LEVO ER 61.25-245 CP has ranged from a low of $3.7464 (Apr 22, 2026) to a high of $3.9497 (Nov 11, 2026), with a median of $3.7776 per EA.

Are there cheaper alternatives to CARBIDOPA-LEVO ER 61.25-245 CP?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RYTARY ER 61.25 MG-245 MG CAP, is $3.5009 per EA — about 11% below CARBIDOPA-LEVO ER 61.25-245 CP.

Who manufactures CARBIDOPA-LEVO ER 61.25-245 CP?

CARBIDOPA-LEVO ER 61.25-245 CP (NDC 70710214201) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.